Gossamer Bio said Tuesday that its experimental drug for pulmonary arterial hypertension achieved the main goal of a mid-stage clinical trial. But the treatment effect was smaller than expected, raising concerns that the drug may not be potent enough to provide a meaningful benefit for patients.
Shares of Gossamer fell 64% to $3 in early trading.
Pulmonary arterial hypertension, or PAH, is a chronic, progressive condition in which high blood pressure in the arteries of the lungs leads to difficulty breathing and walking.
About the Author Reprints
Create a display name to comment
This name will appear with your comment
